Brief: Quantum Genomics Announces Interim Analysis From Renal Failure Study
May 6 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* ANNOUNCES INTERIM ANALYSIS FROM STUDY OF FIRIBASTAT IN
RENAL
FAILURE PATIENTS
Source text for Eikon: ID:nGNX4PnG71
Further company coverage: ALQGC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study